Effect of semaglutide on weight loss and glycaemic control in patients with Prader-Willi Syndrome and type 2 diabetes

Endocrinol Diabetes Nutr (Engl Ed). 2024 Feb;71(2):83-87. doi: 10.1016/j.endien.2023.12.001.

Abstract

Prader-Willi Syndrome (PWS) is the most common genetic cause of obesity, occurring in approximately 1 in 15,000 newborns. It results from the lack of expression of genes on the paternal allele of the chromosomal region 15q-11q13 (65-75% due to type 1 or type 2 deletion). Individuals with PWS experience associated symptoms such as hypotonia, hyperphagia, and early-onset obesity (before 5 years of age). Around 20% of adults with PWS also develop type 2 diabetes. Previous studies have shown the beneficial effects of GLP1-RA medications, such as exenatide and liraglutide, in treating type 2 diabetes in PWS. However, there is limited information available on the use of semaglutide in PWS. This study aimed to evaluate the effects of semaglutide on weight loss and glycaemic control in four patients with PWS and type 2 diabetes associated with obesity. The patients were started on weekly subcutaneous progressive doses of semaglutide.

Keywords: Diabetes mellitus; Obesidad; Obesity; Prader–Willi Syndrome; Semaglutida; Semaglutide; Síndrome de Prader-Willi.

Publication types

  • Review

MeSH terms

  • Adult
  • Diabetes Mellitus, Type 2* / complications
  • Diabetes Mellitus, Type 2* / drug therapy
  • Glucagon-Like Peptides*
  • Glycemic Control / adverse effects
  • Humans
  • Infant, Newborn
  • Obesity / complications
  • Obesity / drug therapy
  • Prader-Willi Syndrome* / drug therapy
  • Weight Loss

Substances

  • semaglutide
  • Glucagon-Like Peptides